The Fly | CRBU

Today

Citizens biotech analysts hold an analyst/industry conference call

3:21 PM

Over a week ago

Caribou Biosciences presents ANTLER trial results at EHA

CRBU

Jun 11, 8:55 AM

FDA Commissioner Marty Makary resigns

+17

May 12, 1:58 PM

Caribou Biosciences price target raised by $2 at H.C. Wainwright, here's why

CRBU

May 11, 6:17 AM

Caribou CB-011 granted Regenerative Medicine Advanced Therapy designation

CRBU

Mar 31, 8:06 AM

Caribou Biosciences price target raised by $2 at Evercore ISI, here's why

CRBU

Mar 9, 8:05 AM

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

CRBU

Mar 5, 4:23 PM

Caribou Biosciences initiated with bullish view at Clear Street, here's why

CRBU

Feb 2, 4:22 PM

Caribou Biosciences price target lowered by $2 at BofA, here's why

CRBU

Jan 6, 10:14 AM

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

CRBU

Nov 12, 5:24 PM

FDA appoints Richard Pazdur as Director of CDER

+16

Nov 11, 4:27 PM

Caribou Biosciences price target raised by $6 at H.C. Wainwright, here's why

CRBU

Nov 5, 6:17 AM

Caribou Biosciences price target raised by $3 at Citi, here's why

CRBU

Nov 3, 10:13 AM

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

CRBU

Nov 3, 7:15 AM

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

CRBU

Nov 3, 7:14 AM

Video: This stock is dragging down the in vivo gene editing therapy space

Oct 27, 1:53 PM

Intellia Therapeutics price target lowered by $6 at BofA, here's why

Oct 27, 11:27 AM

Caribou Biosciences reports Q2 EPS (35c), one estimate (42c)

CRBU

Aug 12, 4:59 PM

No more stories

Proprietary chRDNA Genome Editing Platform: Caribou Biosciences possesses a unique and proprietary Cas9 hybrid RNA-DNA (chRDNA) genome editing technology, which offers enhanced precision, specificity, and potentially reduced off-target editing compared to traditional CRISPR systems, forming the foundation of their therapeutic development.

Advanced Allogeneic Cell Therapy Design: Their lead allogeneic CAR-T cell therapy candidates, such as CB-010, incorporate sophisticated genome edits including PD-1 knockout to prevent T-cell exhaustion and B2M knockout to avoid host rejection, aiming for improved efficacy and durability in an "off-the-shelf" format.

Robust Intellectual Property Portfolio: Caribou holds a strong and foundational intellectual property estate around CRISPR-Cas9 genome editing, particularly concerning their chRDNA technology and methods for engineering cells, which provides a significant barrier to entry for competitors.

Clinical Trial Failure Risk: Caribou's drug candidates are in early stages of clinical development, and many drug candidates fail to demonstrate safety and efficacy in clinical trials, which could lead to significant delays, increased costs, or complete abandonment of programs.

Regulatory Approval Uncertainty Risk: Obtaining regulatory approval for gene-edited therapies is a complex, lengthy, and highly uncertain process, and Caribou may not receive necessary approvals from regulatory authorities, or approvals may be subject to restrictive conditions.

Intense Competition Risk: The gene-editing and cell therapy fields are highly competitive and rapidly evolving, with numerous established pharmaceutical companies and emerging biotechs developing similar or superior technologies and product candidates, potentially limiting Caribou's market share or pricing power.